Synergic insulin sensitizing effect of rimonabant and BGP-15 in Zucker-obese rats

Related Experiment Video

Updated: May 11, 2026

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

Zsuzsanna Literati-Nagy1, Kálmán Tory, Botond Literáti-Nagy

  • 1Department of Medical Chemistry, Molecular Biology and Pathobiochemistry, Semmelweis University, Budapest, Hungary.

Pathology Oncology Research : POR
|May 4, 2013
PubMed

Insights

This study shows that combining BGP-15 with rimonabant enhances insulin sensitivity in obese rats. This combination may allow for lower, safer doses of rimonabant to treat insulin resistance and type 2 diabetes.

Area of Science:

  • Metabolic disorders
  • Pharmacology
  • Endocrinology

Background:

  • Abdominal obesity is a key factor in metabolic syndrome, contributing to insulin resistance, dyslipidemia, hypertension, and inflammation.
  • Rimonabant, a cannabinoid-1 receptor (CB1R) blocker, improves insulin sensitivity but has psychiatric side effects.
  • Insulin resistance is a major hallmark of type 2 diabetes and metabolic syndrome.

Purpose of the Study:

  • To investigate the combined effects of BGP-15 and rimonabant on insulin resistance in Zucker obese rats.
  • To determine if lower doses of rimonabant can be used effectively when combined with BGP-15.
  • To explore the potential role of capsaicin-induced signaling in the insulin-sensitizing effects of these compounds.

Main Methods:

  • Administration of selected doses of BGP-15 and rimonabant to Zucker obese rats.
  • Assessment of insulin signaling pathways and insulin sensitivity.
  • Evaluation of the synergistic effects of the drug combination.

Main Results:

  • BGP-15 potentiated the insulin-sensitizing effects of rimonabant.
  • The combination therapy improved insulin signaling at doses that were ineffective individually.
  • Capsaicin-induced signaling pathways may contribute to the insulin-sensitizing actions of both BGP-15 and rimonabant.

Conclusions:

  • Combined BGP-15 and rimonabant therapy can enhance insulin sensitization.
  • Lower doses of rimonabant may be sufficient for treating insulin resistance and type 2 diabetes when used in combination, potentially reducing adverse psychiatric effects.
  • This combination strategy offers a promising approach for managing metabolic disorders.

More Related Videos

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...